Ometid IR 40 mg+1100 mg (Capsule (Immediate Release)) is a brand of the generic Omeprazole + Sodium Bicarbonate. It is manufactured by Opsonin Pharma Ltd..

Capsule (Immediate Release) Ometid IR Capsule (Immediate Release)

40 mg+1100 mg
Unit Price: ৳ 7.00 (30's pack: ৳ 210.00)
Also available as:

Indications

Duodenal Ulcer: Omeprazole & Sodium bicarbonate is indicated for short-term treatment of active duodenal ulcer. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 

Gastric Ulcer: Omeprazole & Sodium bicarbonate is indicated for short-term treatment (4-8 weeks) of active benign gastric ulcer. 

Treatment Of Gastroesophageal Reflux Disease (GERD):
  • Symptomatic GERD: Omeprazole & Sodium bicarbonate is indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks.
  • Erosive Esophagitis: Omeprazole & Sodium bicarbonate is indicated for the short-term treatment (4-8 weeks) of erosive esophagitis which has been diagnosed by endoscopy. The efficacy of Omeprazole & Sodium bicarbonate used for longer than 8 weeks in these patients has not been established. If a patient does not respond to 8 weeks of treatment, it may be helpful to give up to an additional 4 weeks of treatment. If there is recurrence of erosive esophagitis or GERD symptoms (e.g., heartburn), additional 4-8 week courses of Omeprazole & Sodium bicarbonate may be considered.
Maintenance Of Healing Of Erosive Esophagitis: Omeprazole & Sodium bicarbonate is indicated to maintain healing of erosive esophagitis. Controlled studies do not extend beyond 12 months.

Reduction Of Risk of Upper Gastrointestinal Bleeding In Critically Ill Patients (40mg oral suspension only): Omeprazole & Sodium bicarbonate Powder for Oral Suspension 40 mg/1680 mg is indicated for the reduction of risk of upper GI bleeding in critically ill patients. [See Clinical Studies, Reduction of Risk of Upper Gastrointestinal Bleeding in Critically Ill Patients]

Therapeutic Class

Other drugs used for peptic ulcer disease

Pharmacology

Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus. belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus.

Sodium bicarbonate raises blood and urinary pH by dissociation to provide bicarbonate ions, which neutralises the hydrogen ion concentration. It also neutralises gastric acid via production of carbon dioxide.

Dosage

Since both the 20 mg and 40 mg capsules contain the same amount of sodium bicarbonate (1100 mg), two capsules of 20 mg are not equivalent to one capsule of 40 mg; therefore, two 20 mg capsules should not be substituted for one capsule 40 mg.

Short-Term Treatment of Active Duodenal Ulcer
: 20 mg Once daily for 4 weeks

Benign Gastric Ulcer: 40 mg Once daily for 4-8 weeks

Symptomatic GERD (with no esophageal erosions): 20 mg Once daily for up to 4 weeks

Erosive Esophagitis: 20 mg Once daily for 4-8 weeks

Maintenance of Healing of Erosive Esophagitis: 20 mg Once daily

Reduction of Risk of Upper Gastrointestinal Bleeding in Critically Ill Patients (40 mg oral suspension only): 40 mg initially followed by 40 mg 6-8 hours later and 40 mg daily thereafter for 14 days

Administration

Should be taken on an empty stomach. Take at least 1 hr before a meal.

Interaction

Diazepam, warfarin, phenytoin, drugs metabolized by oxidation in the liver, cyclosporine, disulfiram, benzodiazepines, ketoconazole, ampicillin esters, Fe salts, atazanavir, tacrolimus, clarithromycin.

Contraindications

Metabolic alkalosis & hypocalcemia. Pregnancy.

Side Effects

Abdominal pain, asthenia, constipation, diarrhea, flatulence, nausea, vomiting, acid regurgitation, headache

Pregnancy & Lactation

Pregnancy Category C. Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.

Precautions & Warnings

Patients on Na-restricted diet; Bartter's syndrome, hypokalemia, resp alkalosis, problems with acid-base balance. Severe hepatic impairment. Lactation. Childn & adolescents <18 yr.